Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06013241 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
A Phase 2 study, sponsored by Insmed Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 288
- Enrollment target
NCT06013241 is a Phase 2 study that has completed, run by Insmed Incorporated. The registered enrollment target is 288 participants.
The verdict
NCT06013241, a Phase 2 study, has completed, sponsored by Insmed Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 288 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
Interventions
- DRUG Placebo
- DRUG Mometasone furoate nasal spray (MFNS)
- DRUG Brensocatib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2025-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06013241
The ClinicalTrials.gov registry entry for NCT06013241 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06013241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06013241 about?
NCT06013241 is a clinical study titled "A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)". The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
What is the current status of trial NCT06013241?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 288 participants. The study started on 2023-10-30. Estimated completion is 2025-10-30.
What interventions are being tested in trial NCT06013241?
The interventions under investigation include: Placebo (DRUG), Mometasone furoate nasal spray (MFNS) (DRUG), Brensocatib (DRUG).
Who is sponsoring clinical trial NCT06013241?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.